<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000617667"><TermName>tanespimycin</TermName><TermPronunciation>(ta-NEH-spih-MY-sin)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of cancer. It is made from an antibiotic called geldanamycin. Tanespimycin helps cause the breakdown of certain proteins in the cell, and may kill cancer cells. It is a type of antineoplastic antibiotic and a type of HSP90 inhibitor. Also called 17-AAG and 17-N-allylamino-17-demethoxygeldanamycin.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000723055" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tanespimycin&quot;" language="en" id="_3"/><MediaLink ref="CDR0000723054" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tanespimicina&quot;" language="es" id="_4"/><SpanishTermName>tanespimicina</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Está elaborada con un antibiótico que se llama geldanamicina. La tanespimicina ayuda a descomponer ciertas proteínas de la célula y podría destruir células cancerosas. Es un tipo de antibiótico antineoplásico y un tipo de inhibidor de la HSP90. También se llama 17-AAG y 17-N-alilamino-17-demetoxigeldanamicina.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-10-15</DateFirstPublished><DateLastModified>2008-10-15</DateLastModified></GlossaryTerm>
